Background: First-line treatment of post-traumatic stress disorder (PTSD) is trauma-focused psychotherapy. If drug treatment is indicated, then selective serotonin reuptake inhibitors are the first choice. Other drugs studied include prazosin, antipsychotics and antiseizure medications. Aim: A case report of the marked improvement in the patient's rehabilitation following appropriately treating PTSD symptoms with prazosin. Clinical details: A 28-year-old man was admitted to the Rehabilitation Ward, at Redcliffe Hospital, with a right quadricep tendon rupture which had been repaired 3 months previously. The patient was not able to weight-bear and was admitted in a wheelchair. Past medical history included epilepsy and PTSD treated with quetiapine to assist sleep. Since quetiapine was not managing the PTSD symptoms it was ceased and prazosin was commenced to decrease PTSD nightmares. Outcomes: Sleep quality and decreased trauma nightmares were significantly improved after commencement of prazosin. The patient progressed from being wheelchair-bound to being more ambulant on discharge. Conclusion: Prazosin is effective for enhanced sleep quality, reduction in trauma nightmares and marked reduction in PTSD symptoms. Better control of PTSD symptoms may have an impact on recovery and rehabilitation.
INTRODUCTION
Post-traumatic stress disorder (PTSD) can occur following a traumatic event. It is characterised by symptoms that include nightmares, flashbacks, avoidance, problems concentrating and difficulties in sleeping.
Prazosin is an alpha-adrenergic blocking agent, with Therapeutic Goods Administration approval for the following indications: hypertension, congestive heart failure, benign prostatic hyperplasia, Raynaud's phenomenon and Raynaud's disease. 1 Prazosin dampens excessive brain noradrenergic activity reported in PTSD and has been shown consistently to improve the quality of sleep and reduce nightmares in PTSD. 2, 3 Prazosin offers a novel and inexpensive approach to nightmare reduction and the relief of other PTSD symptoms. 4 
CASE REPORT
A 28-year-old man was admitted to the Rehabilitation Ward from the community. His presenting complaint was a right quadricep tendon rupture, which had been repaired at another hospital. The rupture repair had occurred 3 months earlier and within 3 weeks of the repair, it became infected. The patient presented to the Redcliffe Hospital and had two washouts and was commenced on intravenous flucloxacillin with the Hospital in the Home (HITH) program. At his review at outpatients, now 2 months after the repair, it was decided to readmit the patient for debridement. The patient was then discharged with HITH on intravenous piperacillin and tazobactam. Three months after the repair, HITH were concerned that the patient was not improving as he was not able to weight-bear and still used a wheelchair for mobility. He was referred to the Redcliffe Hospital for rehabilitation.
His past medical history revealed epilepsy, treated with sodium valproate enteric coated tablets, 1000 mg three times a day. Epileptic treatment had started at 14 years of age, with the last seizure being 4 years ago.
Past psychiatric history was PTSD as a result of physical abuse by his father during childhood and being raped by a man. He suffers from flashbacks and recurrent nightmares. PTSD treatment was quetiapine 25 mg at night to help sleep.
On admission to the Rehabilitation Ward at the Redcliffe Hospital his regular medications were continued, with the exception of the antibiotic. The intravenous piperacillin and tazobactam was changed to oral flucloxacillin. This was then reviewed at day 6 of admission and ceased on the basis of C-reactive protein <2.0. He participated in a rehabilitation program to strengthen his muscles as they were weak following the lack of mobility over the previous 3 months and he had been using a wheelchair for mobility. The patient experienced vivid, horrific nightmares during his inpatient stay that necessitated him being moved to a single room. As part of the multidisciplinary rehabilitation team the pharmacist undertook a medication review to exclude the possibility of medication-induced nightmares. No medications were implicated; however, due to failure to suppress the nightmares, quetiapine 25 mg was ceased.
Prazosin 1 mg at night was begun in an attempt to reduce his nightmares with the dose increased to 2 mg on day 10 of his admission. The staff reported that there had been no nightmares and that the patient had atypically, slept soundly and well. Blood pressure monitoring after commencement of prazosin revealed only minor postural hypotension.
His rehabilitation improved, with the patient progressing from wheelchair status to ambulating with the help of a walking stick. After 14 days in the rehabilitation ward, he was discharged (non-wheelchair-bound) on prazosin 2 mg at night (with potential to increase the dose of prazosin, if required) and referred to a psychiatrist with trauma training.
DISCUSSION
PTSD is a trauma-and stressor-related disorder that a person may develop after experiencing or witnessing an extreme, overwhelming traumatic event during which they felt intense fear, helplessness or horror. For a PTSD diagnosis, symptoms must persist for more than 1 month. 5 Symptoms are grouped into three categories: 5 1 intrusive symptoms (re-experiencing the event)
such as flashbacks, intrusive thoughts, nightmares, as if the traumatic event were recurring 2 avoidance symptoms, including numbing, social withdrawal and deliberately trying to keep the trauma event out of mind, loss of interest in activities that previously had brought enjoyment, restricting emotional responses, and 3 hyper-arousal symptoms, such as sleep problems, difficulty falling asleep and exaggerated startle response, irritability, anger, poor concentration and memory.
Symptoms may be of immediate onset (within the first 3 months after the trauma) or delayed onset where symptoms may be delayed by months, or even years (e.g. in cases of child abuse). Symptom reactivation may occur in response to reminders of the original trauma, life stressors, or new traumatic events. 5 Prognosis is improved if therapy is initiated soon after the trauma. 5 Psychotherapy (trauma-focused) should be started in a safe environment as soon as possible after the traumatic event. Cognitive behaviour therapy, eye movement desensitisation and reprocessing aim to teach emotional regulation skills that change how the victim feels and acts by changing patterns of thinking and behaviour. Chronic PTSD sufferers may need to focus on better control of symptoms, e.g. anger or anxiety management, stress reduction, etc. Group support may have a role in chronic PTSD. 6, 7 Therapeutic Guidelines: Psychotropic 8 recommends selective serotonin reuptake inhibitors (SSRIs) as the first-line pharmacotherapy treatment option for PTSD, if required as an adjunct to psychotherapy. Since PTSD patients are usually aware of somatic reactions such as nausea and headache, doses are usually gradually increased. Present recommendations suggest treatment of PTSD with medication, 4-8 weeks after trauma if symptoms are still present. SSRIs reduce the three categories of symptoms of PTSD: intrusive, hyper-arousal and avoidance. Response is slower than for depression and thus the drug trial should be for at least 8-12 weeks and if beneficial, continued for 12 months. Current evidence from randomised controlled trials for pharmacotherapy of PTSD shows limited efficacy of mirtazapine, tricyclic antidepressants and antipsychotics such as risperidone, quetiapine and olanzapine. Anti-seizure medications, e.g. carbamazepine, may reduce aggression by acting on the central nervous system to reduce neuronal hyper-excitability associated with aggression, but further research is needed to clarify the role of anti-seizure medications in PTSD. [8] [9] [10] Benzodiazepines are ineffective for PTSD treatment and prevention.
quality more than placebo (Table 1) . In these studies, prazosin doses ranged from 1 to 20 mg/day, with a starting dose of 1 mg. Noradrenaline has a role in the pathophysiology of PTSD. Higher noradrenaline cerebrospinal fluid concentrations have been found in patients with PTSD and are associated with greater severity of PTSD symptoms. 14 This increased central nervous system noradrenergic state contributes to the disruption of normal rapid eye movement sleep, in turn contributing to nightmares. 15 Thus, blocking post-synaptic adrenergic receptors is a possible pharmacologic approach to the treatment of PTSD-associated nightmares.
Our patient suffered from recurrent trauma nightmares which caused disturbed sleep. Until the commencement of prazosin therapy, he could not remember a night that he had slept soundly. Since sleep is a fundamental physiologic phenomenon known to restore physical and mental health, the attainment of adequate quality sleep plays a vital role in health and wellbeing. The patient had disturbed sleep on a nightly basis and it was only after initiating prazosin that his sleep improved. By reducing trauma nightmares, prazosin improved sleep quality and may have also assisted with the marked improvement in his rehabilitation.
CONCLUSION
Prazosin has been found to be effective in decreasing nightmares and improving sleep quality in PTSD. In this case history, nightmares and subsequent poor sleep quality may have impacted the restoration of our patient's physical health. Prazosin, in decreasing nightmares and improving sleep quality, may have provided a positive impact on the recovery and rehabilitation.
The rehabilitation journey for this patient was remarkable and after only 14 days, mobility status improved from wheelchair-bound to walking with a stick.
This case also highlights the importance of reviewing medications for all conditions, not only the presenting condition. The pharmacist is an integral member of the multidisciplinary rehabilitation team working to deliver improved patient outcomes. 
